VRTX Q4 2022 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.3B+11.1% YoY

Gross Profit

$2.0B87.7% margin

Operating Income

$1.0B44.9% margin

Net Income

$819M35.6% margin

EPS (Diluted)

$3.15

QoQ Revenue Growth

-1.4%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$1.0B

Stock-Based Comp.

$112M

Balance Sheet

Total Assets

$18.2B

Total Liabilities

$4.2B

Stockholders' Equity

$13.9B

Cash & Equivalents

$10.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.3B	$2.1B	+11.1%
Gross Profit	$2.0B	$1.8B	+10.6%
Operating Income	$1.0B	$878M	+17.8%
Net Income	$819M	$770M	+6.3%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.0B88%

KALYDECO

$136M6%

ORKAMBI

$111M5%

SYMDEKO/SYMKEVI

$34M1%

Geographic Segments

UNITED STATES

$1.5B63%

Europe

$687M30%

Other, Non U.S.

$155M7%